← Back to Search

Radiopharmaceutical

131I-PSMA-1095 Radioligand Therapy (RLT) for Prostate Cancer (CROSSBOW Trial)

Phase 2

Waitlist Available

Led By Stephan Probst, MD

Research Sponsored by Sir Mortimer B. Davis - Jewish General Hospital

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 3 months post last dose of rlt

Awards & highlights

CROSSBOW Trial Summary

This trial is testing a new treatment for prostate cancer in 200 men. The treatment involves using a radioactive substance to target and kill cancer cells. The trial will assess how well the treatment works by measuring the amount of cancer cells remaining after treatment.

Eligible Conditions

Prostate Cancer
Prostate Adenocarcinoma

CROSSBOW Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 3 months post last dose of rlt

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~3 months post last dose of rlt

This trial's timeline: 3 weeks for screening, Varies for treatment, and 3 months post last dose of rlt for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Prostate-Specific Antigen

Secondary outcome measures

Adverse events

CROSSBOW Trial Design

1Treatment groups

Experimental Treatment

Group I: 131I-PSMA-1095 Radioligand Therapy (RLT)Experimental Treatment1 Intervention

Intravenous injection of 100 mCi of 131I-PSMA-1095 RLT, Q8 weeks up to a maximum of 4 doses

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Sir Mortimer B. Davis - Jewish General HospitalLead Sponsor

55 Previous Clinical Trials

21,149 Total Patients Enrolled

14 Trials studying Prostate Cancer

3,668 Patients Enrolled for Prostate Cancer

Stephan Probst, MDPrincipal InvestigatorJewish General Hospital

1 Previous Clinical Trials

2,000 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any openings currently available for this research trial?

"According to clinicaltrials.gov, the recruitment period for this trial has ended; initially posted on July 31st 2020 and last edited on October 24th 2022. Although no longer recruiting patients, there are 2039 other medical trials actively looking for individuals at present."

Answered by AI

To what degree is 131I-PSMA-1095 Radioligand Therapy (RLT) considered risk-free for individuals?

"As the clinical trial is currently in Phase 2, and there being limited data on efficacy but some evidence of safety, our team from Power have assigned a rating of 2 to 131I-PSMA-1095 Radioligand Therapy (RLT)."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Two TraCer PositROn EmiSSion Tomography ComBination for Efficacy EstimatiOn of Prostate Specific Membrane Antigen Radioligand Therapy in Patients With Metastatic Prostate Cancer

Stephan Probst, MD 2020. "Two TraCer PositROn EmiSSion Tomography ComBination for Efficacy EstimatiOn of Prostate Specific Membrane Antigen Radioligand Therapy in Patients With Metastatic Prostate Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04085991.